Table 3.
Prognostic factors in CMML*
*
Results of multivariate analysis of survival and risk of AML evolution in the study by Such et al.7
†(1) Low-risk, normal karyotype or loss of Y chromosome as a single anomaly; (2) high-risk, presence of trisomy 8 or abnormalities of chromosome 7 or complex karyotype; and (3) intermediate-risk, all other abnormalities. The actuarial median survival of patients within these 3 cytogenetic risk groups was 37, 18, and 11 months, respectively.
